|
Infliximab
resources
|
|
|
|
|
|
DRUG INFO
Infliximab
Drug Name:
Infliximab
Indication: For treatment of Crohn's disease, psoriasis, rheumatoid arthitis and ankylosing spondylitis
Pharmacology: Used in the treatment of auto-immune disorders such as Crohn'€™s disease and rheumatoid arthritis. Infliximab binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.
Mechanism Of Action: Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa
Drug Category: Immunomodulatory Agents; Immunosuppresants; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Ig gamma-1 chain C region; Remicade (Centocor Inc)
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Chimeric mouse/human anti-TNF-alpha antibody (cA2)
Chemical Formula: C6428H9912N1694O1987S46 >Mouse-Human chimeric chain 1 Anti-TNF alpha VL >Mouse-Human chimeric chain 2 Anti-TNF alpha VH >Mouse-Human chimeric chain 2 Anti-TNF alpha VL
Half Life: 9.5 days
Drug Type: Approved Drug
# Accession No: BIOD00004
CAS Registry Number: 331731-18-1
|
|
|
|
|
|
Infliximab News
(When available)
Back pain relief may be within your reach 16 Jan 2006
Daytona Beach News-Journal, ...past few years, due to a scientific breakthrough, several biologic agents known as "anti-tumor necrosis agents" such as Humira, Enbrel and Remicade have proven ...
Efficacy of Remicade in patients with ulcerative colitis Dec 28, 2005
Xagena.it, Patients with moderate-to-severe active ulcerative colitis treated with Infliximab ( Remicade ) at weeks 0, 2, and 6 and every eight weeks thereafter were more ...
New treatments for rheumatoid arthritis Jan 14, 2006
Packet Online, ...advances in RA treatment involve a new group of anti-inflammatory medications called biologic response modifiers, including Enbrel, Humira, Kineret and Remicade ...
Blanchard pushing NB to help with drug expenses Jan 3, 2006
Canada East, As well, he has had to take many painkillers. But an expensive drug called Remicade changed his life. ... He said he could hardly move before taking Remicade. ...
Medicare expands tier pricing system Jan 3, 2006
USA Today ...patients will most commonly pay 25% to 33% of the cost of the drug rather than a flat dollar amount — are such expensive treatments as Remicade and Enbrel ...
Bob Feldman Jan 14, 2006
Charlotte Observer, He was 55. He helped start Centocor, which is best known for developing Remicade, a drug for rheumatoid arthritis and Crohn's disease. ...
New Drugs Offer More Choices for Psoriasis Dec 21, 2005
Spartanburg Herald Journal (subscription), In late 2002, her longtime dermatologist, Dr. Terry Hadley of Concord, Mass., started her on infusions of infliximab, sold as Remicade, a new so-called ...
New Treatment Promising For Ulcerative Colitis Sufferers Jan 4, 2006
Innovations-Report, ...trials. UK was a primary investigator of infliximab, brand name Remicade®, and enrolled the largest study group in North America. ...
Treatment shows promise for treating colitis Dec 27, 2005
CTV.ca, The study of more than 360 patients found that a drug called Remicade provides relief to sufferers with moderately-to-severely active colitis, a disease caused ...
Bristol-Myers gets FDA approval for arthritis drug Dec 24, 2005
Economic Times, ...therapies. Older treatments include Abbott Laboratories Inc's Humira, Johnson & Johnson's Remicade and Amgen Inc's Enbrel. Three ...
Nikkei 225 Rises to Highest Since September 2000; Sharp Jumps Jan 11, 2006
Bloomberg Eisai surged 350 yen, or 7.1 percent, to 5,270, while Tanabe, which makes Remicade, an arthritis treatment, jumped 90 yen, or 7.3 percent, to 1,320. ...
Biologic drugs the latest psoriasis weapon Dec 20, 2005
United Press International However, a host of biologic drugs -- led by Centocor Inc.'s Remicade -- have resulted in major improvements for numerous psoriasis sufferers, The New York ...
Chemist who helped found Pa. biotech industry dies at 55 Jan 4, 2006
Philadelphia Inquirer, In 1998, the company won approval from federal regulators for Remicade, a treatment for Crohn's disease and later rheumatoid arthritis. ...
Juvenile Arthritis - A Niche In The Market Dec 20, 2005
Pharmaceutical Business Review Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). ...
US okay for B-MS' blockbuster candidate Jan 2, 2006
Pharma Times (subscription), ...rheumatic drugs (DMARDs) such as methotrexate but also the new anti-tumor necrosis factor products such as Johnson & Johnson's Remicade (infliximab), Wyeth's ...
Phila. biotech luminary dies Jan 3, 2006
Philadelphia Business Journal, ...the company survived the failure of its first lead product and later cracked the billion-dollar mark in sales, led by its rheumatoid arthritis drug Remicade. ...
UCB initiated with "neutral" Jan 4, 2006
New Ratings ...note published this morning, the analyst mentions that Cimzia may witness significant market share gains in the Crohn's disease segment with Remicade as the ...
Bristol-Myers Shares Gain in Europe After US Clears Drug Dec 27, 2005
Bloomberg Existing treatments for rheumatoid arthritis include Enbrel, sold by Amgen Inc. and Wyeth, Johnson & Johnson's Remicade and Abbott Laboratories' Humira. ...
Bristol-Myers shrs up 2 pct after Orencia approval Dec 27, 2005
Washington Post, ...treatments. Those treatments include big-selling drugs, such as Amgen Inc.'s Enbrel and Johnson & Johnson Inc.'s Remicade. "The ...
Bristol-Myers shrs up 2 pct after Orencia approval Dec 27, 2005
Reuters ...big-selling drugs, such as Amgen Inc.'s (AMGN.O: Quote, Profile, Research) Enbrel and Johnson & Johnson Inc.'s (JNJ.N: Quote, Profile, Research) Remicade. ...
Bristol-Myers Squibb Receives US Approval for Arthritis Drug Dec 23, 2005
New York Times, ...status. Orencia will compete with Enbrel by Amgen, Remicade by Johnson & Johnson and Humira by Abbott - all called anti-TNF agents. ...
Bristol Climbs on FDA Approval Dec 27, 2005
Red Herring, However, the company faces competition from some older medications, such as Johnson & Johnson’s Remicade and Amgen’s Enbrel. ...
Colleges seek to make scientific research pay off Dec 19, 2005
MSNBC ...on research. NYU made most of its money from royalties on the drug Remicade, used to treat arthritis and other conditions. A more ...
S&P Upgrades Univision to Strong Buy Dec 27, 2005
BusinessWeek However, its potential is limited by the FDA's restriction of the drug to patients who fail to respond to existing drugs, such as Enbrel and Remicade. ...
Mixing meds and supplements could be dangerous Dec 28, 2005
Asbury Park Press, ...since he had his knee replaced four years ago. "I take Remicade for my rheumatoid arthritis. I also take folic acid and the anti ...
FDA OKs Bristol-Myers rheumatoid arthritis drug Dec 23, 2005
Herald News Daily, ...received a placebo. Enbrel, Remicade and Humira are TNF-alpha inhibitors, which block a protein linked to inflammation. The FDA ...
|
|
|
